HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
50 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
CD40LG
CD40 ligand
Chromosome X Β· Xq26.3
NCBI Gene: 959Ensembl: ENSG00000102245.9HGNC: HGNC:11935UniProt: P29965
548PubMed Papers
21Diseases
6Drugs
105Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedHub Gene
RESEARCH IMPACT
Highly StudiedVariant-Rich
CLINICAL
Clinical TrialsOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
positive regulation of interleukin-10 productionpositive regulation of interleukin-12 productionpositive regulation of interleukin-4 productionGO:0005615hyper-IgM syndrome type 1X-linked hyper-IgM syndromehyper-IgM syndromegenetic disorder
✦AI Summary

CD40LG encodes CD40 ligand, a critical immunoregulatory protein expressed on activated T cells and other immune cells. The primary function of CD40LG is to bind CD40 receptor on B cells, dendritic cells, and other antigen-presenting cells, facilitating essential immune interactions 1. This CD40-CD40LG interaction is required for T cell-dependent B cell activation, proliferation, and differentiation, as well as dendritic cell licensing to activate CD8+ T cells 2. The signaling pathway involves NF-ΞΊB activation and production of various cytokines and chemokines 1. CD40LG deficiency causes X-linked hyper-IgM syndrome type 1, characterized by decreased IgG, IgA, and IgE with normal or elevated IgM levels, leading to recurrent sinopulmonary infections and opportunistic pathogens 3. Novel mutations like c.156 G>T can cause disease through nonsense-mediated mRNA decay 4. In autoimmune diseases like systemic lupus erythematosus, CD40LG is overexpressed due to DNA hypomethylation, leading to excessive B cell stimulation and IgG production 5. The clinical significance extends to cancer therapy, where CD40 agonists are being investigated as immunotherapeutic agents 2, and CD40LG expression serves as a prognostic marker in lung adenocarcinoma 6.

Sources cited
1
CD40LG binds CD40 receptor and mediates immune/inflammatory responses through NF-ΞΊB signaling
PMID: 11229815
2
CD40-CD40LG interaction facilitates B cell activation and dendritic cell licensing of CD8+ T cells
PMID: 38102001
3
CD40LG deficiency causes X-linked hyper-IgM syndrome with characteristic immunoglobulin profile and infections
PMID: 31831191
4
Novel CD40LG mutations like c.156 G>T cause disease through nonsense-mediated mRNA decay
PMID: 32500460
5
CD40LG overexpression in lupus due to DNA hypomethylation leads to excessive B cell stimulation
PMID: 19520616
6
CD40LG expression serves as prognostic marker in lung adenocarcinoma
PMID: 40840227
Disease Associationsβ“˜21
hyper-IgM syndrome type 1Open Targets
0.85Strong
X-linked hyper-IgM syndromeOpen Targets
0.84Strong
hyper-IgM syndromeOpen Targets
0.55Moderate
genetic disorderOpen Targets
0.41Moderate
common variable immunodeficiencyOpen Targets
0.40Weak
Sjogren syndromeOpen Targets
0.37Weak
systemic lupus erythematosusOpen Targets
0.33Weak
ulcerative colitisOpen Targets
0.28Weak
sarcoidosisOpen Targets
0.24Weak
neurodegenerative diseaseOpen Targets
0.22Weak
inflammatory bowel diseaseOpen Targets
0.21Weak
rheumatoid arthritisOpen Targets
0.14Weak
IGA glomerulonephritisOpen Targets
0.12Weak
neoplasmOpen Targets
0.12Weak
COVID-19Open Targets
0.12Weak
infectionOpen Targets
0.12Weak
chronic lymphocytic leukemiaOpen Targets
0.12Weak
type 1 diabetes mellitusOpen Targets
0.12Weak
malariaOpen Targets
0.11Weak
dengue diseaseOpen Targets
0.11Weak
Immunodeficiency with hyper-IgM, type 1UniProt
Pathogenic Variants105
NM_000074.3(CD40LG):c.506A>G (p.Tyr169Cys)Likely pathogenic
not provided|Hyper-IgM syndrome type 1
β˜…β˜…β˜†β˜†2026β†’ Residue 169
NM_000074.3(CD40LG):c.761C>T (p.Thr254Met)Pathogenic
Hyper-IgM syndrome type 1
β˜…β˜…β˜†β˜†2025β†’ Residue 254
NM_000074.3(CD40LG):c.31C>T (p.Arg11Ter)Pathogenic
Hyper-IgM syndrome type 1|not specified|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 11
NM_000074.3(CD40LG):c.158_161delPathogenic
Hyper-IgM syndrome type 1
β˜…β˜…β˜†β˜†2024
NM_000074.3(CD40LG):c.520C>T (p.Gln174Ter)Pathogenic
Hyper-IgM syndrome type 1
β˜…β˜…β˜†β˜†2024β†’ Residue 174
NM_000074.3(CD40LG):c.654C>A (p.Cys218Ter)Pathogenic
Hyper-IgM syndrome type 1
β˜…β˜…β˜†β˜†2024β†’ Residue 218
NM_000074.3(CD40LG):c.431G>A (p.Gly144Glu)Likely pathogenic
not provided|Hyper-IgM syndrome type 1
β˜…β˜…β˜†β˜†2024β†’ Residue 144
NM_000074.3(CD40LG):c.347-2A>GPathogenic
not provided|Hyper-IgM syndrome type 1
β˜…β˜…β˜†β˜†2024
NM_000074.3(CD40LG):c.559del (p.Ala187fs)Pathogenic
Inborn genetic diseases|Hyper-IgM syndrome type 1
β˜…β˜…β˜†β˜†2023β†’ Residue 187
NM_000074.3(CD40LG):c.268C>T (p.Gln90Ter)Pathogenic
Hyper-IgM syndrome type 1|not provided
β˜…β˜…β˜†β˜†2023β†’ Residue 90
NM_000074.3(CD40LG):c.658C>T (p.Gln220Ter)Pathogenic
not provided|Hyper-IgM syndrome type 1
β˜…β˜…β˜†β˜†2022β†’ Residue 220
NM_000074.3(CD40LG):c.478C>T (p.Gln160Ter)Pathogenic
Hyper-IgM syndrome type 1
β˜…β˜…β˜†β˜†2022β†’ Residue 160
NM_000074.3(CD40LG):c.373C>T (p.His125Tyr)Pathogenic
Hyper-IgM syndrome type 1
β˜…β˜…β˜†β˜†2022β†’ Residue 125
NM_000074.3(CD40LG):c.107T>G (p.Met36Arg)Pathogenic
Hyper-IgM syndrome type 1
β˜…β˜…β˜†β˜†2022β†’ Residue 36
NM_000074.3(CD40LG):c.346+5G>APathogenic
Hyper-IgM syndrome type 1|not provided
β˜…β˜…β˜†β˜†2022
NM_000074.3(CD40LG):c.767T>C (p.Phe256Ser)Likely pathogenic
not provided|Hyper-IgM syndrome type 1
β˜…β˜…β˜†β˜†2020β†’ Residue 256
NM_000074.3(CD40LG):c.208C>T (p.Gln70Ter)Pathogenic
Hyper-IgM syndrome type 1
β˜…β˜†β˜†β˜†2026β†’ Residue 70
NM_000074.3(CD40LG):c.34dup (p.Ser12fs)Pathogenic
Hyper-IgM syndrome type 1
β˜…β˜†β˜†β˜†2025β†’ Residue 12
NM_000074.3(CD40LG):c.138del (p.His47fs)Pathogenic
Hyper-IgM syndrome type 1
β˜…β˜†β˜†β˜†2025β†’ Residue 47
NM_000074.3(CD40LG):c.409+1delPathogenic
Hyper-IgM syndrome type 1
β˜…β˜†β˜†β˜†2025
View on ClinVar β†—
Drug Targets6
DAPIROLIZUMAB PEGOLPhase III
CD40 ligand inhibitor
systemic lupus erythematosus
DAZODALIBEPPhase III
CD40 ligand antagonist
Sjogren syndrome
RAVAGALIMABPhase II
CD40 ligand antagonist
ulcerative colitis
RUPLIZUMABPhase II
CD40 ligand inhibitor
kidney transplant
TEGOPRUBARTPhase II
CD40 ligand inhibitor
amyotrophic lateral sclerosis
TORALIZUMABPhase I
CD40 ligand inhibitor
Thrombocytopenia
Related Genes
CD8AProtein interaction100%TNFRSF1BProtein interaction100%IFNGProtein interaction99%FASProtein interaction98%FASLGProtein interaction98%BCL6Protein interaction98%
Tissue Expression6 tissues
Bone Marrow
100%
Lung
68%
Liver
15%
Heart
8%
Ovary
4%
Brain
0%
Gene Interaction Network
Click a node to explore
CD40LGCD8ATNFRSF1BIFNGFASFASLGBCL6
PROTEIN STRUCTURE
Preparing viewer…
PDB6W9G Β· 1.82 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.28Highly Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.06 [0.02–0.28]
RankingsWhere CD40LG stands among ~20K protein-coding genes
  • #452of 20,598
    Most Researched548 Β· top 5%
  • #732of 5,498
    Most Pathogenic Variants105 Β· top quartile
  • #953of 17,882
    Most Constrained (LOEUF)0.28 Β· top 10%
Genes detectedCD40LG
Sources retrieved50 papers
Response timeβ€”
πŸ“„ Sources
50β–Ό
1
CD40 Ligand Deficiency.
PMID: 31831191
Allergol Immunopathol (Madr) Β· 2020
1.00
2
Harnessing the potential of CD40 agonism in cancer therapy.
PMID: 38102001
Cytokine Growth Factor Rev Β· 2024
0.90
3
Two novel CD40LG gene mutations causing X-linked hyper IgM syndrome in Vietnamese patients.
PMID: 34842998
Clin Exp Med Β· 2023
0.88
4
Modified CD40L-Activated B-Cell Proliferation Model for Validating the Suppressive Activity of CD40-CD154 Pathway Inhibitors.
PMID: 39994946
Xenotransplantation Β· 2025
0.86
5
Role of Skewed X-Chromosome Inactivation in Common Variable Immunodeficiency.
PMID: 38265673
J Clin Immunol Β· 2024
0.80